Safety and efficacy of radioallergosorbent test-based allergen immunotherapy in treatment of perennial allergic rhinitis and asthma
Presented at the Annual Meeting of the American Academy of Otolaryngic Allergy, San Diego, CA, September 20, 2002.
Objective
This study was undertaken to demonstrate the safety and efficacy of in vitro, radioallergosorbent test (RAST)-based inhalant allergen immunotherapy.
Study design and setting
Prospective 22 year single site clinical study, with outcome evaluations of 480 perennial allergic rhinitis patients, including 96 with concomitant asthma.
Results
Rhinitis symptom control after 2 years of immunotherapy was excellent in 32.5% of patients, good in 45.6%, and fair in 14.2%. There was no improvement in 7.7%. For patients with asthma, 81% had good or excellent pulmonary symptom improvement, and no patient failed to improve. No severe reactions occurred, but there were 5 limited systemic reactions, or 0.008% of injections, during a 2.5-year mean immunotherapy treatment course.
Conclusion
RAST-based immunotherapy is safe and effective for patients with perennial allergic rhinitis, with or without concomitant asthma.
Significance
This is the first large, multiyear study of safety and efficacy of RAST-based immunotherapy for treatment of perennial allergic rhinitis and asthma. EBM rating: C.
aNational University of Singapore, Department of Otolaryngology, Singapore(Drs Yeoh and Wang)
bDepartment of Otology and Laryngology, Harvard University, Massachusetts Eye and Ear Infirmary, and Cape Cod Hospital, Division of Otolaryngology, Boston, MA, USA (Dr Gordon)
Reprint requests: Bruce R. Gordon, MD, Cape Cod ENT Specialists, 65 Cedar St., Hyannis, MA 02601
ABSTRACT